Metis Global Partners LLC Has $7.33 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Posted by Brian Himes on Jun 11th, 2026

Metis Global Partners LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 23.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,654 shares of the medical research company’s stock after selling 3,963 shares during the quarter. Metis Global Partners LLC’s holdings in Thermo Fisher Scientific were worth $7,332,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Howard Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock worth $1,791,000 after acquiring an additional 16 shares in the last quarter. Petros Family Wealth LLC lifted its holdings in Thermo Fisher Scientific by 3.9% during the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock worth $264,000 after buying an additional 17 shares in the last quarter. Salomon & Ludwin LLC lifted its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after buying an additional 17 shares in the last quarter. Pallas Capital Advisors LLC lifted its holdings in Thermo Fisher Scientific by 1.5% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock worth $728,000 after buying an additional 18 shares in the last quarter. Finally, Red Door Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 0.8% during the 4th quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock worth $1,250,000 after buying an additional 18 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $483.13 on Thursday. The business’s fifty day moving average is $480.02 and its 200-day moving average is $528.89. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a market cap of $179.54 billion, a P/E ratio of 26.56, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on TMO shares. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $613.67.

Get Our Latest Analysis on TMO

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.